Warning Letters: DanChem Technologies and Medsep - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Warning Letters: DanChem Technologies and Medsep

Pharmaceutical Technology

Warning Letters: DanChem Technologies and Medsep

The US Food and Drug Administration this week released drug-product warning letters sent to DanChem Technologies (Danville, VA, www.danchem.com) and Medsep Corp. (Covina, CA).

On March 3, FDA's Baltimore (MD) District Office sent a three-page letter to DanChem, an active-pharmaceutical-ingredient maker. The letter cited "physical filth" contamination found by a customer in several lots of calcium polycarbophil. The warning also cited "significant violations of current good manufacturing practice" found during agency inspections last fall, including:
  • blending out-of-specification calcium polycarbophil with in-spec batches to bring the combined batches within specification;
  • omitting ingredient names and weights from batch records;
  • maintaining "inaccurate" disposal records by labeling, disposing of, and recording debris-filled ontainers as "rejected API";
  • failure to review batch records that indicated that the amount of material produced exceeded the capacity of the processing equipment; and
  • failure to investigate foreign material found in manufacturing equipment.

On Feb. 15, the Los Angeles District Office (Irvine, CA) sent a letter to Medsep (a subsidiary of Pall Corp., East Hills, NY, www.pall.com), dealing mainly with procedural and record-keeping shortcomings in the manufacture of bacterial detection devices used with oxygen analyzers. The inspection did note, however, that "Anticoagulant Citrate Phospahate Double Dextrose Solution with AS-3 Nuhicel Additive System" (used in blood collection bags manufactured at the same facility) are regulated under drug CGMPs, and cited inadequacies in the batch production and control records.

–Doug McCormick

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here